<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829439</url>
  </required_header>
  <id_info>
    <org_study_id>08-10-0490</org_study_id>
    <nct_id>NCT00829439</nct_id>
  </id_info>
  <brief_title>Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome</brief_title>
  <official_title>A Dose-escalation Tolerability Study of Levodopa/Carbidopa in Angelman Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the highest dose of levodopa/carbidopa that can be&#xD;
      tolerated without any serious side effects by children with Angelman syndrome.&#xD;
&#xD;
      It has been hypothesized that levodopa may lead to an improvement in the neurodevelopment and&#xD;
      abnormal movements (e.g. tremors) in children with Angelman syndrome.&#xD;
&#xD;
      Data from this study will be used to design a phase II trial to determine the efficacy of&#xD;
      levodopa in treating children with Angelman syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Levodopa is a prodrug that &quot;delivers&quot; dopamine to the brain. It is usually given with&#xD;
      carbidopa, a peripheral decarboxylase inhibitor, to increase the bioavailability of levodopa.&#xD;
      Animal studies have suggested that levodopa can reverse the excess phosphorylation of some&#xD;
      enzymes involved in synaptic and neuronal function, including calcium/calmodulin-dependent&#xD;
      kinase type 2 (CaMKII).&#xD;
&#xD;
      Recently, it was shown that excess phosphorylation of CaMKII may be responsible for some of&#xD;
      the neurological deficits seen in Angelman syndrome. Therefore, it is hypothesized that&#xD;
      levodopa may lead to an improvement in the neurodevelopment and abnormal movements (e.g.&#xD;
      tremors) in children with Angelman syndrome.&#xD;
&#xD;
      Although many children have used levodopa for a variety of medical conditions over the last&#xD;
      30 years, it has not been approved by the Food and Drug Administration (FDA) for use in&#xD;
      children, and it has not been formally studied in children with Angelman syndrome, so we do&#xD;
      not know what dose of levodopa is most appropriate for children with Angelman syndrome.&#xD;
&#xD;
      Therefore, the purpose of this study is to find out the highest dose of levodopa that&#xD;
      children with Angelman syndrome can tolerate without any serious side effects.&#xD;
&#xD;
      Once we know the dose of levodopa that can be tolerated by children with Angelman syndrome,&#xD;
      we will conduct a larger follow-up study to find out whether levodopa will lead to an&#xD;
      improvement in their development and tremor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Dose of Levodopa/Carbidopa That Can be Tolerated (Without Any Dose Limiting Toxicity) by at Least 3 Subjects.</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Angelman Syndrome</condition>
  <arm_group>
    <arm_group_label>Levodopa/Carbidopa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Other Names:&#xD;
Sinemet L-dopa&#xD;
Dosages are based on levodopa.&#xD;
Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.&#xD;
Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa/Carbidopa (4:1)</intervention_name>
    <description>Dosages are based on levodopa.&#xD;
Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.&#xD;
Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.</description>
    <arm_group_label>Levodopa/Carbidopa</arm_group_label>
    <other_name>Sinemet</other_name>
    <other_name>L-dopa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Angelman syndrome, confirmed by molecular testing&#xD;
&#xD;
          -  Must be willing to come for research visit on 2 days, exactly 1 week apart&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  On levodopa, carbidopa, or any dopamine agonists in the 2 weeks prior to participation&#xD;
&#xD;
          -  Other medical conditions that may be associated with developmental or cognitive delays&#xD;
&#xD;
          -  More than 2 clinical seizures per month&#xD;
&#xD;
          -  Used monoamine oxidase (MAO) inhibitors within the last 2 weeks&#xD;
&#xD;
          -  Used phenytoin within the last 2 weeks&#xD;
&#xD;
          -  Used phenothiazines, butyrophenones, and thioxanthenes within last 2 weeks&#xD;
&#xD;
          -  Hypersensitive to levodopa or carbidopa&#xD;
&#xD;
          -  Cardiovascular disease or instability&#xD;
&#xD;
          -  Respiratory diseases, including asthma, emphysema, chronic cough, and shortness of&#xD;
             breath&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Stomach or intestinal ulcers&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  Hematological problems, including anemia, leucopenia, and thrombocytopenia&#xD;
&#xD;
          -  Used investigational drugs/interventions within the past three months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Hann Tan, BMBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <results_first_submitted>August 5, 2016</results_first_submitted>
  <results_first_submitted_qc>September 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2016</results_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Wen-Hann Tan</investigator_full_name>
    <investigator_title>Attending Physician in Genetics</investigator_title>
  </responsible_party>
  <keyword>Angelman syndrome</keyword>
  <keyword>Levodopa</keyword>
  <keyword>Carbidopa</keyword>
  <keyword>L-dopa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angelman Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Levodopa/Carbidopa 2 mg/kg/Day</title>
          <description>Levodopa at 2 mg/kg/day in 3 divided doses</description>
        </group>
        <group group_id="P2">
          <title>Levodopa / Carbidopa 5 mg/kg/Day</title>
          <description>Levodopa 5 mg/kg/day in 3 divided doses</description>
        </group>
        <group group_id="P3">
          <title>Levodopa / Carbidopa 10 mg/kg/Day</title>
          <description>Levodopa 10 mg/kg/day in 3 divided doses</description>
        </group>
        <group group_id="P4">
          <title>Levodopa / Carbidopa 15 mg/kg/Day</title>
          <description>Levodopa / Carbidopa 15 mg/kg/day in 3 divided doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levodopa/Carbidopa</title>
          <description>Other Names:&#xD;
Sinemet L-dopa&#xD;
Dosages are based on levodopa.&#xD;
Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.&#xD;
Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.&#xD;
Levodopa/Carbidopa (4:1): Dosages are based on levodopa.&#xD;
Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.&#xD;
Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Dose of Levodopa/Carbidopa That Can be Tolerated (Without Any Dose Limiting Toxicity) by at Least 3 Subjects.</title>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Other Names:&#xD;
Sinemet L-dopa&#xD;
Dosages are based on levodopa.&#xD;
Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.&#xD;
Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.&#xD;
Levodopa/Carbidopa (4:1): Dosages are based on levodopa.&#xD;
Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.&#xD;
Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Dose of Levodopa/Carbidopa That Can be Tolerated (Without Any Dose Limiting Toxicity) by at Least 3 Subjects.</title>
          <units>mg/kg/day</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Levodopa/Carbidopa</title>
          <description>Other Names:&#xD;
Sinemet L-dopa&#xD;
Dosages are based on levodopa.&#xD;
Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.&#xD;
Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.&#xD;
Levodopa/Carbidopa (4:1): Dosages are based on levodopa.&#xD;
Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.&#xD;
Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Shaky or Unsteady on feet</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wen-Hann Tan</name_or_title>
      <organization>Boston Children's Hospital</organization>
      <phone>617-355 6394</phone>
      <email>wen-hann.tan@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

